AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1856145
Drug: Three injections
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three injections of tobramycin (1.5 mg/kg)
Trial: 1856145
Drug: Single injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection of amikacin
Trial: 6343143
Drug: Cimetidine and
RxNorm normalized name: Cimetidine and sodium alginate only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine and chlorpheniramine in combination
Trial: 30468136
Drug: Mindfulness group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness group therapy (MGT)
Trial: 30468136
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (mostly cognitive-behavioral therapy)
Trial: 28767146
Drug: Red wine
RxNorm normalized name: Red wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red wine (RW) 375 ml/d for 4 weeks
Trial: 25602465
Drug: S‐CBT (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S‐CBT (standard cognitive‐behavioral treatment)
Trial: 25602465
Drug: A‐CBT (culturally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A‐CBT (culturally accommodated cognitive‐behavioral treatment)
Trial: 24471459
Drug: Minoxidil 2%
RxNorm normalized name: MINOXIDIL 2% SOLN,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minoxidil 2% lotion
Trial: 19581463
Drug: Meropenem 10
RxNorm normalized name: meropenem 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem 10 mg/kg
Trial: 19581463
Drug: Meropenem 20
RxNorm normalized name: meropenem 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem 20 mg/kg
Trial: 19581463
Drug: Meropenem 40
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meropenem 40 mg/kg
Trial: 19581463
Drug: 8-hour dosing
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-hour dosing interval
Trial: 19581463
Drug: 12-hour dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-hour dosing interval
Trial: 19581463
Drug: 0.5-hour infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5-hour infusion time
Trial: 19581463
Drug: 4-hour infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-hour infusion time
Trial: 8174828
Drug: Adrenergic blockers
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenergic blockers (propranolol and phentolamine)
Trial: 8174828
Drug: Stressful stimuli
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stressful stimuli or adrenergic blockers
Trial: 28323893
Drug: Supervised exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised exercise training (3 weekly sessions of 35 minutes moderate intensity walking/running followed by 25 minutes strength training)
Trial: 26152322
Drug: Hydrocortisone 10
RxNorm normalized name: hydrocortisone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone 10 mg/d
Trial: 26152322
Drug: Hydrocortisone 30
RxNorm normalized name: hydrocortisone 30 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone 30 mg/d
Trial: 26152322
Drug: Hydrocortisone therapies
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone therapies (10 mg/d and 30 mg/d)
Trial: 18308788
Drug: Methylphenidate (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (mean dose: 14.7 mg; range: 10-30 mg)
Trial: 16834582
Drug: Benson Relaxation
RxNorm normalized name: Relax-DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benson Relaxation Technique (BRT) combined with medication
Trial: 16834582
Drug: Only medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Only medication (control group)
Trial: 11709742
Drug: Dose-dense ADoc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-dense ADoc regimen (4 cycles of Doxorubicin 50 mg/m², Docetaxel 75 mg/m² i.v. day 1, q day 15 or 22; G-CSF day 3-15 only for the dose-dense schedule)
Trial: 9821453
Drug: High serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High serum lithium levels (0.8‐1.0 mmol L‐1)
Trial: 9821453
Drug: Low serum
RxNorm normalized name: ZINC OXIDE 20 g in 100 mL TOPICAL CREAM [Sunceutical SPF 50 Mineral Glow Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low serum lithium levels (0.5‐0.8 mmol L‐1)
Trial: 9821453
Drug: Lithium treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium treatment (both high and low levels)
Trial: 7815279
Drug: Intranasal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal insulin formulation (delivered volumes of 80-160 microL)
Trial: 25724407
Drug: Oral palonosetron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral palonosetron (0.50 mg) with oral dexamethasone
Trial: 25724407
Drug: IV palonosetron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV palonosetron (0.25 mg) with oral dexamethasone
Trial: 25724407
Drug: Oral palonosetron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral palonosetron (0.50 mg)
Trial: 25724407
Drug: IV palonosetron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV palonosetron (0.25 mg)
Trial: 22020357
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + fluoxetine (≤80 mg/d of fluoxetine)
Trial: 22020357
Drug: Clomipramine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine + fluoxetine (≤75 and ≤40 mg/d, respectively)
Trial: 22020357
Drug: Quetiapine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine + fluoxetine (≤200 and ≤40 mg/d, respectively)
Trial: 19635614
Drug: BZA 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BZA 20 mg with CE 0.625 mg
Trial: 19635614
Drug: BZA 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BZA 40 mg with CE 0.45 mg
Trial: 19635614
Drug: BZA 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BZA 10 mg with CE 0.625 mg
Trial: 16757491
Drug: Primary PCI
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary PCI with 300 mg loading dose of clopidogrel
Trial: 15300231
Drug: Cyclosporine (CS)
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (CS) 3 mg/kg/day intravenously, with subsequent oral dosing
Trial: 15300231
Drug: Cyclosporine (CS)
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (CS) plus Methotrexate (MTX) 15 mg/m2 on day 1, and 10 mg/m2 on days 3, 6, and 11
Trial: 8138651
Drug: Intramuscular nefopam
RxNorm normalized name: nefopam
DrugBank: Nefopam (DB12293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular nefopam
Trial: 23897052
Drug: Oxiplex gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxiplex gel (carboxymethylcellulose/polyethylene oxide gel) applied during surgery
Trial: 10900154
Drug: Methotrexate (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (5 mg/m(2)/week)
Trial: 10900154
Drug: No immunosuppressive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No immunosuppressive treatment (Control)
Trial: 1474534
Drug: Nabumetone (2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nabumetone (2000 mg/day)
Trial: 22218138
Drug: Placebo (intermittent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (intermittent ultrasound therapy)
Trial: 16213926
Drug: Short-term immunotherapy
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term immunotherapy (STI) with molecular standardized allergens (ALK(7), n = 24) plus anti-allergic drugs
Trial: 16213926
Drug: Anti-allergic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-allergic drugs alone (n = 24)
Trial: 12145716
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B colloidal dispersion (ABCD; 6 mg/kg/day)
Trial: 12145716
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B (AmB; 1.0-1.5 mg/kg/day)
Trial: 8379178
Drug: Systemic intravenous
RxNorm normalized name: Vaginal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic intravenous infusions (SVI)
Trial: 3510660
Drug: Ketoconazole, 200
RxNorm normalized name: Ketoconazole, 200 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole, 200 mg twice daily for male partners
Trial: 29168473
Drug: Yangxin Tongmai
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yangxin Tongmai Formula (YTF) administered orally for 60 days
Trial: 25912854
Drug: Intravenous antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous antibiotics (clindamycin or first-generation cephalosporin) for 2 to 4 days followed by oral antibiotics for 20 to 30 days
Trial: 25912854
Drug: Intravenous antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous antibiotics (clindamycin or first-generation cephalosporin)
Trial: 20307730
Drug: 3.6 mL
RxNorm normalized name: ALCOHOL 2.7 mL in 3.6 mL TOPICAL CLOTH [hand sanitizers]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.6 mL of 2% lidocaine with 1:100,000 epinephrine
Trial: 14725657
Drug: Sclerosing foam
RxNorm normalized name: SCLEROSING AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sclerosing foam (polidocanol 3% solution, 2.0 or 2.5 mL injection)
Trial: 14725657
Drug: Sclerosing liquid
RxNorm normalized name: SCLEROSING AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sclerosing liquid (polidocanol 3% solution, 2.0 or 2.5 mL injection)
Trial: 30071830
Drug: Sports Stars
RxNorm normalized name: Star Anise Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sports Stars intervention (eight, one-hour, weekly physiotherapy group sessions)
Trial: 26443600
Drug: Gel-filling technique
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel-filling technique (GF)
Trial: 24845165
Drug: Buprenorphine taper
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine taper (4-week duration)
Trial: 21169166
Drug: Internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive behavioral therapy (n = 88)
Trial: 21169166
Drug: Internet-based problem-solving
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based problem-solving therapy (n = 88)
Trial: 16173650
Drug: Ramelteon (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramelteon (16 mg)
Trial: 16173650
Drug: Ramelteon (64
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramelteon (64 mg)
Trial: 16173650
Drug: Ramelteon (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramelteon (16 or 64 mg)
Trial: 12930012
Drug: Actifed DM
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Actifed DM plus paracetamol (ADM/P group)
Trial: 31138731
Drug: Clenil pressurized
RxNorm normalized name: Clenia
DrugBank: Octasulfur (DB09353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clenil pressurized metered‐dose inhaler (pMDI; 250 μg) with spacer
Trial: 31138731
Drug: Qvar Easi‐Breathe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qvar Easi‐Breathe inhaler (100 μg) with spacer
Trial: 29228091
Drug: nab-paclitaxel 150
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nab-paclitaxel 150 mg/m2 days 1 and 15 Q28 (arm A)
Trial: 29228091
Drug: nab-paclitaxel 100
RxNorm normalized name: paclitaxel 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nab-paclitaxel 100 mg/m2 days 1, 8 and 15 Q28 (arm B)
Trial: 29228091
Drug: nab-paclitaxel 75
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nab-paclitaxel 75 mg/m2 days 1, 8, 15 and 22 Q28 (arm C)
Trial: 22492249
Drug: New gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New gel medical device (Proctoial) containing hyaluronic acid, tea tree oil, and methyl-sulfonyl-methane
Trial: 21416034
Drug: Community intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community intervention training health workers to train community-based women groups in recognizing malaria symptoms and providing first-line treatment.
Trial: 17040305
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of OND and MET
Trial: 17040305
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment with OND, MET, and DEX
Trial: 12968984
Drug: Omapatrilat 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omapatrilat 2.5 mg (single dose)
Trial: 12968984
Drug: Omapatrilat (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omapatrilat (multiple doses: 10, 25, 50, 75, or 125 mg daily for 10 days)
Trial: 12968984
Drug: Omapatrilat (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omapatrilat (single dose)
Trial: 12968984
Drug: Omapatrilat (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omapatrilat (single and multiple doses)
Trial: 12968984
Drug: Omapatrilat (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omapatrilat (multiple doses)
Trial: 12968984
Drug: Omapatrilat (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omapatrilat (doses > 7.5 mg)
Trial: 9760791
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium (Tilade-8 mg/24 hours)
Trial: 3838321
Drug: Minocycline hydrochloride
RxNorm normalized name: Minocycline Hydrochloride
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Minocycline hydrochloride with iron (300 mg ferrous sulfate)
Trial: 3838321
Drug: Tetracycline hydrochloride
RxNorm normalized name: Tetracycline Hydrochloride
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tetracycline hydrochloride with iron (300 mg ferrous sulfate)
Trial: 25824259
Drug: Topical moxifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical moxifloxacin (0.5%) administered as one drop four times at 15-minute intervals starting 75 minutes before surgery.
Trial: 25824259
Drug: Oral moxifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral moxifloxacin (400 mg) administered as a single tablet 12 hours before surgery.
Trial: 21346614
Drug: Aripiprazole (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (15 mg/d)
Trial: 12126263
Drug: Moxonidine 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxonidine 0.6 mg o.d.
Trial: 9651560
Drug: 8 g
RxNorm normalized name: Theranost 68 Ga Rgd
DrugBank: NODAGA-THERANOST Ga-68 (DB16940)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 g cholestyramine and 20 mg pravastatin
Trial: 2693326
Drug: Combined endocrine
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined endocrine therapy (Tamoxifen with prednisolone or androgens)
Trial: 342319
Drug: 7 log
RxNorm normalized name: triamcinolone acetonide Injectable Suspension [Sano Log]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 log EID50/dose
Trial: 342319
Drug: 6 log
RxNorm normalized name: triamcinolone acetonide Injectable Suspension [Sano Log]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 log EID50/dose
Trial: 342319
Drug: 7 log
RxNorm normalized name: triamcinolone acetonide Injectable Suspension [Sano Log]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 log EID50/dose (twice vaccinated)
Trial: 342319
Drug: 6 log
RxNorm normalized name: triamcinolone acetonide Injectable Suspension [Sano Log]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 log EID50/dose (twice vaccinated)
Trial: 31043770
Drug: 0.5 µg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 µg/mL dexmedetomidine with 0.1% ropivacaine
Trial: 31043770
Drug: 0.5 µg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 µg/mL sufentanil with 0.1% ropivacaine
Trial: 21697824
Drug: D2 receptor
RxNorm normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D2 receptor blockade (sulpiride (SULP) 400 mg)
Trial: 19681862
Drug: R-salbutamol cream
RxNorm normalized name: (R)-salbutamol
DrugBank: Levosalbutamol (DB13139)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: R-salbutamol cream 0.5%
Trial: 3288523
Drug: Ketotifen (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen (1 mg twice daily for under 5-year-olds, 2 mg twice daily for others)
Trial: 31856493
Drug: Subthreshold micropulse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subthreshold micropulse yellow laser (SMYL) and intravitreal aflibercept injection (IAI) combination therapy
Trial: 31856493
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept injection (IAI) monotherapy
Trial: 20171080
Drug: Intrathecal magnesium
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal magnesium sulphate 50 mg
Trial: 20171080
Drug: 0.1 mL
RxNorm normalized name: ethanol 0.1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mL of 0.9% sodium chloride (control group)
Trial: 18074471
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin G (ivIgG) 0.6 g/kg body weight on day 0 and 0.3 g/kg body weight on day 1
Trial: 18074471
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin G (ivIgG)
Trial: 16214045
Drug: Oral tegafur
RxNorm normalized name: tegafur
DrugBank: Tegafur (DB09256)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Oral tegafur (FT) 750 mg/m2/day for 21 days and leucovorin (LV) 15 mg/m2 every 8 h in cycles repeated every 28 days
Trial: 16214045
Drug: Intravenous leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous leucovorin (LV) 20 mg/m2 followed by 5-fluorouracil (5-FU) 425 mg/m2 daily for 5 days every 4 weeks for 2 cycles, and later every 5 weeks
Trial: 9972958
Drug: Insulin induced
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin induced hypoglycemia
Trial: 9972958
Drug: Thyrotropin releasing
RxNorm normalized name: Thyrotropin releasing factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyrotropin releasing hormone (TRH) stimulation
Trial: 7751513
Drug: Inhaled lysine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled lysine acetylsalicylate and furosemide (720 mg lysine acetylsalicylate and 40 mg furosemide twice daily)
Trial: 12682418
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E supplementation (400 IU daily)
Trial: 6871066
Drug: Fenoctimine 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoctimine 50 mg
Trial: 6871066
Drug: Fenoctimine 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoctimine 150 mg
Trial: 6871066
Drug: Fenoctimine 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoctimine 250 mg
Trial: 23257991
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml kg(‐1) h(‐1) lactated Ringer's solution
Trial: 23257991
Drug: 30 ml
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 ml kg(‐1) h(‐1) lactated Ringer's solution
Trial: 15324520
Drug: CIP/DEX (ciprofloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIP/DEX (ciprofloxacin 0.3%/dexamethasone 0.1%) otic suspension, 3-4 drops twice daily for 7 days
Trial: 15324520
Drug: N/P/H (neomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N/P/H (neomycin 0.35%/polymyxin B 10,000 IU/mL/hydrocortisone 1.0%) otic suspension, 3-4 drops three times daily for 7 days
Trial: 10908255
Drug: BQ‐123 (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BQ‐123 (a selective ET(A) receptor antagonist; 100 nmol/min) in 0.9% saline, infused into the left coronary artery at a rate of 1 ml/min for 60 minutes
Trial: 9302398
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) administration (12.5 or 18 micrograms/kg/day)
Trial: 8094768
Drug: recombinant tissue
RxNorm normalized name: Tissue plasminogen activator, recombinant
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: recombinant tissue plasminogen activator (alteplase, rt-PA) 100 mg over 2 h followed by intravenous heparin
Trial: 30940404
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (20,000 IU of cholecalciferol once weekly for 24 weeks)
Trial: 29797911
Drug: Acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture combined with ibuprofen, methotrexate, and folic acid
Trial: 29797911
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group treatment with ibuprofen, methotrexate, and folic acid
Trial: 27533265
Drug: Supervised physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised physical therapy for upper limbs